These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 26425561)

  • 1. Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
    Wu S; Zheng C; Chen S; Cai X; Shi Y; Lin B; Chen Y
    Biomed Res Int; 2015; 2015():927105. PubMed ID: 26425561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
    Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P
    Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
    Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
    Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
    Niesvizky R; Flinn IW; Rifkin R; Gabrail N; Charu V; Clowney B; Essell J; Gaffar Y; Warr T; Neuwirth R; Zhu Y; Elliott J; Esseltine DL; Niculescu L; Reeves J
    J Clin Oncol; 2015 Nov; 33(33):3921-9. PubMed ID: 26056177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Garderet L; Iacobelli S; Moreau P; Dib M; Lafon I; Niederwieser D; Masszi T; Fontan J; Michallet M; Gratwohl A; Milone G; Doyen C; Pegourie B; Hajek R; Casassus P; Kolb B; Chaleteix C; Hertenstein B; Onida F; Ludwig H; Ketterer N; Koenecke C; van Os M; Mohty M; Cakana A; Gorin NC; de Witte T; Harousseau JL; Morris C; Gahrton G
    J Clin Oncol; 2012 Jul; 30(20):2475-82. PubMed ID: 22585692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
    Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
    Roussel M; Moreau P; Hebraud B; Laribi K; Jaccard A; Dib M; Slama B; Dorvaux V; Royer B; Frenzel L; Zweegman S; Klein SK; Broijl A; Jie KS; Wang J; Vanquickelberghe V; de Boer C; Kampfenkel T; Gries KS; Fastenau J; Sonneveld P
    Lancet Haematol; 2020 Dec; 7(12):e874-e883. PubMed ID: 33242444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
    Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
    Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Moreau P; Avet-Loiseau H; Facon T; Attal M; Tiab M; Hulin C; Doyen C; Garderet L; Randriamalala E; Araujo C; Lepeu G; Marit G; Caillot D; Escoffre M; Lioure B; Benboubker L; Pégourié B; Kolb B; Stoppa AM; Fuzibet JG; Decaux O; Dib M; Berthou C; Chaleteix C; Sebban C; Traullé C; Fontan J; Wetterwald M; Lenain P; Mathiot C; Harousseau JL
    Blood; 2011 Nov; 118(22):5752-8; quiz 5982. PubMed ID: 21849487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
    Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A;
    Blood; 2012 Jul; 120(1):9-19. PubMed ID: 22498745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
    Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Zweegman S; Caillon H; Caillot D; Avet-Loiseau H; Delforge M; Dejoie T; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Schiano de Colella JM; van de Donk NW; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Hua W; Wang J; Tuozzo A; de Boer C; Rowe M; Vanquickelberghe V; Carson R; Vermeulen J; Corre J; Sonneveld P;
    Lancet Oncol; 2024 Aug; 25(8):1003-1014. PubMed ID: 38889735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
    Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
    Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
    Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
    Ludwig H; Viterbo L; Greil R; Masszi T; Spicka I; Shpilberg O; Hajek R; Dmoszynska A; Paiva B; Vidriales MB; Esteves G; Stoppa AM; Robinson D; Ricci D; Cakana A; Enny C; Feng H; van de Velde H; Harousseau JL
    J Clin Oncol; 2013 Jan; 31(2):247-55. PubMed ID: 23091109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.